

World Journal of *Gastrointestinal Oncology*

World J Gastrointest Oncol 2024 December 15; 16(12): 4532-4781



EDITORIAL

- 4532 Mixed neuroendocrine non-neuroendocrine tumors: The quest for evidence
Cives M, Porta C, Palmirotta R
- 4537 Is nutritional status a new indicator to use in clinical practice for colorectal cancer patients?
Berardi R, Chiariotti R, Menstrasti G
- 4543 Gene targets with therapeutic potential in hepatocellular carcinoma
Shodry S, Hasan YTN, Ahdi IR, Ulhaq ZS
- 4548 Estimating prognosis of gastric neuroendocrine neoplasms using machine learning: A step towards precision medicine
Wang HN, An JH, Zong L
- 4553 Exploring Xiaojianzhong decoction's potential in gastric cancer treatment: Integrative insights and experimental validation
Cheng CH, Hao WR, Cheng TH
- 4559 Critical considerations for the management of gastrointestinal mixed neuroendocrine non-neuroendocrine neoplasms and pure neuroendocrine carcinomas
Pavlidis ET, Galanis IN, Pavlidis TE

REVIEW

- 4565 Unraveling the role of cancer-associated fibroblasts in colorectal cancer
Cui JY, Ma J, Gao XX, Sheng ZM, Pan ZX, Shi LH, Zhang BG

ORIGINAL ARTICLE**Case Control Study**

- 4579 Prognostic utility of gamma-glutamyl transpeptidase to platelet ratio in patients with solitary hepatitis B virus-related hepatocellular carcinoma after hepatectomy
Yang CK, Wei ZL, Shen XQ, Jia YX, Wu QY, Wei YG, Su H, Qin W, Liao XW, Zhu GZ, Peng T

Retrospective Cohort Study

- 4597 Prognostic prediction models for postoperative patients with stage I to III colorectal cancer based on machine learning
Ji XL, Xu S, Li XY, Xu JH, Han RS, Guo YJ, Duan LP, Tian ZB
- 4614 Local excision for middle-low rectal cancer after neoadjuvant chemoradiation: A retrospective study from a single tertiary center
Chen N, Li CL, Wang L, Yao YF, Peng YF, Zhan TC, Zhao J, Wu AW

Retrospective Study

- 4625 Risk factors for hepatocellular carcinoma in cirrhosis: A comprehensive analysis from a decade-long study
Zhou DQ, Liu JY, Zhao F, Zhang J, Liu LL, Jia JR, Cao ZH
- 4636 Prognosis of radiotherapy for esophageal cancer in elderly patients exceeding seventy-five years old
Hu LL, Rong F, Liu L, Zhang L, Zhang LL, Yang Q, Xia ZL, Wang H
- 4650 Nomogram model based on γ -glutamyl transferase to albumin ratio predicts survival in hepatocellular carcinoma patients with transarterial chemoembolization treatment
Wu ZY, Li H, Chen JL, Su K, Weng ML, Han YW
- 4663 Deep learning model combined with computed tomography features to preoperatively predicting the risk stratification of gastrointestinal stromal tumors
Li Y, Liu YB, Li XB, Cui XN, Meng DH, Yuan CC, Ye ZX
- 4675 Temozolomide and capecitabine regimen as first-line treatment in advanced gastroenteropancreatic neuroendocrine tumors at a Latin American reference center
Cruz-Diaz WE, Paitan V, Medina J, Flores R, Haro-Varas J, Mantilla R, Castro-Oliden V

Basic Study

- 4685 Vitamin D 1,25-Dihydroxyvitamin D₃ reduces lipid accumulation in hepatocytes by inhibiting M1 macrophage polarization
Luo WJ, Dong XW, Ye H, Zhao QS, Zhang QB, Guo WY, Liu HW, Xu F
- 4700 Matrine promotes colorectal cancer apoptosis by downregulating shank-associated RH domain interactor expression
Zhou YC, Wang QQ, Zhou GYJ, Yin TF, Zhao DY, Sun XZ, Tan C, Zhou L, Yao SK
- 4716 Enhancing the radiosensitivity of colorectal cancer cells by reducing spermine synthase through promoting autophagy and DNA damage
Guo YB, Wu YM, Lin ZZ

META-ANALYSIS

- 4728 Efficacy and safety of transhepatic arterial chemoembolization with drug-loaded microspheres in unresectable primary liver cancer
Deng J, Mi YH, Xie L, Sun XX, Liu DH, Long HJ, He LY, Wu DH, Shang HC

CASE REPORT

- 4738 Mixed pancreatic ductal adenocarcinoma and well-differentiated neuroendocrine tumor: A case report
Zhao X, Bocker Edmonston T, Miick R, Joneja U
- 4746 Signet-ring cell carcinoma of the transverse colon in a 10-year-old girl: A case report
lv L, Song YH, Gao Y, Pu SQ, A ZX, Wu HF, Zhou J, Xie YC

LETTER TO THE EDITOR

- 4753** Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma?
Centrone N, Serrano Uson Junior PL
- 4757** Advancing hepatocellular carcinoma treatment with hepatic arterial infusion chemotherapy
Caliskan Yildirim E, Ergun Y
- 4762** Timely identification and treatment of uterine artery pseudoaneurysm after hysteroscopic procedures
Byeon H
- 4766** Current efficacy of hepatic arterial infusion chemotherapy in hepatocellular carcinoma
Dias E Silva D, Borad M, Uson Junior PLS
- 4770** Use of traditional Chinese medicine bezoars and bezoar-containing preparations in hepatocarcinoma
Li DH, Wen QE, Feng RQ, Qiao C, Tian XT
- 4778** Crosslink among cyclin-dependent kinase 9, ATP binding cassette transporter G2 and Beclin 1 in colorectal cancer
Shao ZB, He K, Su YB, Shi Z

ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Oncology*, Zilvinas Dambrauskas, MD, PhD, Professor, Department of Surgery and Institute for Digestive System Research, Lithuanian University of Health Sciences, Kaunas 50161, Lithuania. zilvinas.dambrauskas@lsmuni.lt

AIMS AND SCOPE

The primary aim of *World Journal of Gastrointestinal Oncology (WJGO, World J Gastrointest Oncol)* is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING

The *WJGO* is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2024 edition of Journal Citation Reports® cites the 2023 journal impact factor (JIF) for *WJGO* as 2.5; JIF without journal self cites: 2.5; 5-year JIF: 2.8; JIF Rank: 72/143 in gastroenterology and hepatology; JIF Quartile: Q3; and 5-year JIF Quartile: Q2. The *WJGO*'s CiteScore for 2023 is 4.2 and Scopus CiteScore rank 2023: Gastroenterology is 80/167; Oncology is 196/404.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Si Zhao*; Production Department Director: *Xiang Li*; Cover Editor: *Jia-Ru Fan*.

NAME OF JOURNAL

World Journal of Gastrointestinal Oncology

ISSN

ISSN 1948-5204 (online)

LAUNCH DATE

February 15, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Monjur Ahmed, Florin Burada

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-5204/editorialboard.htm>

PUBLICATION DATE

December 15, 2024

COPYRIGHT

© 2024 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Current efficacy of hepatic arterial infusion chemotherapy in hepatocellular carcinoma

Douglas Dias E Silva, Mitesh Borad, Pedro Luiz Serrano Uson Junior

Specialty type: Oncology

Provenance and peer review:

Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification

Scientific Quality: Grade D

Novelty: Grade B

Creativity or Innovation: Grade C

Scientific Significance: Grade B

P-Reviewer: Xi Z

Received: July 21, 2024

Revised: August 28, 2024

Accepted: October 12, 2024

Published online: December 15, 2024

Processing time: 113 Days and 14.9 Hours



Douglas Dias E Silva, Department of Oncology, Hospital Israelita Albert Einstein, São Paulo 05652900, Sao Paulo, Brazil

Mitesh Borad, Division of Hematology-Oncology, Department of Medicine, Mayo Clinic Arizona, Mayo Clinic Cancer Center, Phoenix, AZ 85054, United States

Pedro Luiz Serrano Uson Junior, Center for Personalized Medicine, Hospital Israelita Albert Einstein, São Paulo 05652900, Sao Paulo, Brazil

Corresponding author: Pedro Luiz Serrano Uson Junior, MD, Assistant Professor, Center for Personalized Medicine, Hospital Israelita Albert Einstein, Avenida Albert Einstein 627, São Paulo 05652900, Sao Paulo, Brazil. pedro.serrano@einstein.br

Abstract

Newer systemic therapies for hepatocellular carcinoma (HCC) have led to growing interest in combining hepatic arterial infusion chemotherapy (HAIC) with systemic treatments. To evaluate the effectiveness and safety of HAIC and combination therapies in treating advanced HCC, a network meta-analysis was conducted by Zhou *et al.* The study included data from 44 articles. HAIC was superior in overall survival (OS), progression-free survival (PFS), and response rates compared to transarterial chemoembolization and sorafenib. Moreover, combinations of HAIC with other treatments and single agents (*e.g.*, lenvatinib, ablation, anti-programmed cell death 1 therapy, radiotherapy) provided better OS and PFS outcomes than HAIC alone. In this editorial, we will discuss the study findings, the strengths and weaknesses of the metanalysis, and future advances in the field of HAIC for advanced HCC.

Key Words: Hepatic arterial infusion; Chemotherapy; Hepatocellular carcinoma; Liver cancer; Survival

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This meta-analysis provides a valuable and comprehensive evaluation of hepatic arterial infusion chemotherapy (HAIC) and its combination therapies for advanced hepatocellular carcinoma. Compared to other treatments including transarterial chemoembolization, HAIC showed favorable outcomes including response rate and survival. Furthermore, based on the findings, combination of HAIC with antiangiogenics and even immune checkpoint inhibitors seems to improve efficacy when compared to HAIC alone.

Citation: Dias E Silva D, Borad M, Uson Junior PLS. Current efficacy of hepatic arterial infusion chemotherapy in hepatocellular carcinoma. *World J Gastrointest Oncol* 2024; 16(12): 4766-4769

URL: <https://www.wjgnet.com/1948-5204/full/v16/i12/4766.htm>

DOI: <https://dx.doi.org/10.4251/wjgo.v16.i12.4766>

INTRODUCTION

Liver cancer remains a global health challenge, with an estimated incidence of > 1 million cases by 2025[1]. Hepatocellular carcinoma (HCC) is the most common subtype of primary liver cancer, accounting for more than 90% of cases[2,3]. Recent advances in systemic therapies with the inclusion of targeted therapy and immunotherapy have led to changes in many guidelines regarding systemic therapy for advanced disease[4]. Despite these advancements, outcomes related to advanced disease are still poor[5,6]. Another option for the treatment of selected cases of advanced disease is hepatic arterial infusion chemotherapy (HAIC) alone or in combination with other strategies[7]. This therapy is recommended for Japanese guidelines based on studies of this population with promising results, especially for the treatment for advanced HCC with portal vein tumor thrombus[6]. Additionally, there are data showing that HAIC results in fewer adverse events compared to other intra-hepatic therapies, such as transarterial chemoembolization (TACE)[7,8]. Due to the lack of adequate phase 3 randomized controlled trials, there is not enough evidence to confirm that patients with HCC can gain significant benefits from HAIC. Consequently, Zhou *et al*[9] conducted a meta-analysis to provide insight into evidence-based medicine for the use of HAIC.

THE META-ANALYSIS

Zhou *et al*[9] carried out a network meta-analysis examining the effectiveness and safety of HAIC and its combination treatments for advanced HCC. This analysis included data from nine randomized controlled trials and thirty-five cohort studies[9]. Key outcomes assessed included overall survival (OS), progression-free survival (PFS), tumor response, and adverse events, with hazard ratios and odds ratios calculated for comparison. The results indicated that HAIC significantly outperformed Sorafenib and TACE in terms of efficacy and safety. Furthermore, HAIC in combination with therapies such as lenvatinib, ablation, anti-programmed cell death 1 (anti-PD-1), and radiotherapy resulted in improved OS in addition to PFS related to HAIC without association with other toxicities. Moreover, combination therapies such as HAIC with TACE and S-1, HAIC with lenvatinib, and HAIC with anti-PD-1 showed higher partial response rates and objective response rates. Overall, HAIC combined with anti-PD-1, TACE + S-1, and TACE achieved superior complete response and disease control rates compared to HAIC alone. The main results presented by the meta-analysis are described in [Table 1](#).

DISCUSSION

The inclusion of nine randomized controlled trials and 35 cohort studies provides broad and robust data, enhancing the reliability of the findings. Additionally, the study evaluates multiple critical outcomes such as OS, PFS, tumor response, and adverse events, offering a wide overview of the efficacy and safety of HAIC and its combinations. The analysis of HAIC in combination with other treatments (*e.g.*, lenvatinib, programmed cell death 1, radiotherapy) provides valuable insights into potential synergistic effects and paves the way for future trials considering safety data of those regimens. However, the inclusion of both randomized controlled trials and cohort studies, despite increasing the number of patients included in the meta-analysis, could introduce significant heterogeneity in study designs, patient populations, and treatment protocols, potentially impacting the consistency of the results. The findings might not be universally applicable, especially if the included studies predominantly involve certain demographics or regions. Moreover, the studies included do not represent the current landscape of HCC treatment, notably related to the control group, which does not include combined immunotherapy regimens as recommended by current guidelines based on phase III studies compared to tyrosine kinase inhibitors.

When evaluating the quality assessment of trials included, some selection bias inherent to the meta-analysis was identified. For example, most randomized controlled trials were not blinded. This could be very important when evaluating endpoints such as response rate and PFS. Moreover, most studies also had publication bias, easily identified in the funnel plots of responses and adverse events. There are also other limitations important to discuss. Variations in

Table 1 Summary of meta-analysis key findings

Outcome	Number of studies	Main results (HR/OR, 95%CI)	Conclusions and ranking (P value)
OS	41 (9 RCTs, 32 cohorts)	HAIC + Lenv + A: HR = 0.12 (0.03-0.57) HAIC + A: HR = 0.21 (0.07-0.67) HAIC + Lenv: HR = 0.29 (0.11-0.74) HAIC + Sora: HR = 0.52 (0.33-0.81)	HAIC + Lenv + A showed the best OS (P value: 0.94), followed by HAIC + A (P value: 0.85)
PFS	30 (9 RCTs, 21 cohorts)	HAIC + A: HR = 0.25 (0.08-0.77) HAIC + TACE: HR = 0.32 (0.14-0.75) HAIC: HR = 0.51 (0.33-0.78)	HAIC + A had the most favorable PFS outcomes (P value: 0.79)
CR	35 (8 RCTs, 27 cohorts)	HAIC + Sora: OR = 7.62 (2.55-22.77) HAIC: OR = 2.86 (1.37-5.98)	HAIC + Sora showed the best CR outcomes (P value: 0.86)
PR	35 (8 RCTs, 27 cohorts)	HAIC + TACE + S-1: OR = 13.29 (3.63-48.61) HAIC + Lenv: OR = 8.37 (4.32-16.23)	HAIC + TACE + S-1 had the best PR outcomes (P value: 0.90), followed by HAIC + Lenv (P value: 0.79)
ORR	35 (8 RCTs, 27 cohorts)	HAIC + TACE + S-1: OR = 17.88 (2.22-143.80) HAIC + Lenv: OR = 13.92 (3.25-59.60)	HAIC + TACE + S-1 showed the best ORR outcomes (P value: 0.79)
DCR	35 (8 RCTs, 27 cohorts)	HAIC + TACE + S-1: OR = 8.52 (1.56-46.49) HAIC + PD-1: OR = 7.26 (1.97-26.84)	HAIC + TACE + S-1 had the best DCR outcomes (P value: 0.88)
Any grade AEs	12 (4 RCTs, 12 cohorts)	HAIC: OR = 0.48 (0.25-0.92) HAIC + Lenv: OR = 0.19 (0.05-0.72)	HAIC showed the lowest incidence of any grade AEs (P value: 0.85)
Grade 3-4 AEs	16 (5 RCTs, 11 cohorts)	HAIC + Sora: OR = 0.26 (0.07-0.97) HAIC + Lenv: OR = 0.65 (0.12-3.43)	HAIC demonstrated lower trends of grade 3-4 AEs than HAIC + Sora and TACE

A: Anti-angiogenic agent; AEs: Adverse events; CR: Complete response; DCR: Disease control rate; HAIC: Hepatic arterial infusion chemotherapy; HR: Hazard ratio; Lenv: Lenvatinib; OR: Odds ratio; ORR: Objective response rate; OS: Overall survival; PD-1: Programmed death 1; PFS: Progression-free survival; PR: Partial response; RCT: Randomized controlled trial; S-1: Oral fluoropyrimidine (composite preparation of 5-FU prodrug); Sora: Sorafenib; TACE: Transarterial chemoembolization.

HAIC drugs (*i.e.* cisplatin or oxaliplatin), dosing regimens and drug dosages in the studies included were not considered. This could result in varying efficacy and safety profiles. The inclusion of anti-PD-1 without specifying the drug and the exclusion of some relevant studies due to their small number could also impact the interpretation of the findings and exacerbate the publication bias. Finally, the inability to conduct a subgroup analysis for portal vein tumor thrombus despite its recommendation in Japanese guidelines limits the analysis's applicability to this specific condition.

It is important to note that standard first-line treatment for advanced HCC is currently based on immunotherapy for eligible patients[10]. Combinations like durvalumab and tremelimumab, atezolizumab and bevacizumab, sintilimab and IBI305 and nivolumab plus ipilimumab are superior to tyrosine kinase inhibitors for upfront treatment in most patients, independently of etiology of cirrhosis or disease burden[10-13]. Furthermore, these combinations associated with TACE have proven to be a very attractive and potent strategy of treatment for patients with intermediate stage (BCLC B)[14]. In the EMERALD1 trial, a combination of TACE with durvalumab and bevacizumab led to an impressive objective response rate of 43%[14]. In conclusion, although HAIC is an important treatment option, it would need to be compared to these regimens to be considered a standard upfront treatment option for most patients with advanced HCC.

CONCLUSION

This meta-analysis provides a valuable and comprehensive evaluation of HAIC and its combination therapies for advanced HCC, highlighting their potential benefits in specific clinical situations, conducted by specialized centers. Significant unmet needs in HCC management could be addressed through the discovery of new therapies and their combinations, particularly for advanced-stage disease. This includes biomarkers for therapy stratification, patient-tailored strategies targeting driver mutations and/or activating signaling cascades, and validated quality-of-life measurements. Based on the findings of this meta-analysis, HAIC should be investigated with more potent and modern regimens to improve outcomes for this challenging disease.

FOOTNOTES

Author contributions: Dias e Silva D, Borad M, and Uson Junior PLS wrote and revised the article, reviewed the literature, and approved the final version of the manuscript.

Conflict-of-interest statement: The authors declare no conflicts-of-interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to

distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country of origin: Brazil

ORCID number: Pedro Luiz Serrano Uson Junior [0000-0001-6122-1374](https://orcid.org/0000-0001-6122-1374).

S-Editor: Lin C

L-Editor: Filipodia

P-Editor: Chen YX

REFERENCES

- Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. *Nat Rev Dis Primers* 2021; **7**: 6 [PMID: [33479224](https://pubmed.ncbi.nlm.nih.gov/33479224/) DOI: [10.1038/s41572-020-00240-3](https://doi.org/10.1038/s41572-020-00240-3)]
- Forner A, Reig M, Bruix J. Hepatocellular carcinoma. *Lancet* 2018; **391**: 1301-1314 [PMID: [29307467](https://pubmed.ncbi.nlm.nih.gov/29307467/) DOI: [10.1016/S0140-6736\(18\)30010-2](https://doi.org/10.1016/S0140-6736(18)30010-2)]
- Brown ZJ, Tsilimigras DI, Ruff SM, Mohseni A, Kamel IR, Cloyd JM, Pawlik TM. Management of Hepatocellular Carcinoma: A Review. *JAMA Surg* 2023; **158**: 410-420 [PMID: [36790767](https://pubmed.ncbi.nlm.nih.gov/36790767/) DOI: [10.1001/jamasurg.2022.7989](https://doi.org/10.1001/jamasurg.2022.7989)]
- Kudo M. Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. *Liver Cancer* 2012; **1**: 62-70 [PMID: [24159574](https://pubmed.ncbi.nlm.nih.gov/24159574/) DOI: [10.1159/000342402](https://doi.org/10.1159/000342402)]
- Ikai I, Kudo M, Arii S, Omata M, Kojiro M, Sakamoto M, Takayasu K, Hayashi N, Makuuchi M, Matsuyama Y, Monden M. Report of the 18th follow-up survey of primary liver cancer in Japan. *Hepatol Res* 2010; **40**: 1043-1059 [PMID: [34818831](https://pubmed.ncbi.nlm.nih.gov/34818831/) DOI: [10.1111/j.1872-034X.2010.00731.x](https://doi.org/10.1111/j.1872-034X.2010.00731.x)]
- Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami T, Yamakado K; Liver Cancer Study Group of Japan. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. *Liver Cancer* 2014; **3**: 458-468 [PMID: [26280007](https://pubmed.ncbi.nlm.nih.gov/26280007/) DOI: [10.1159/000343875](https://doi.org/10.1159/000343875)]
- Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, Chen MS, Shi M. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. *J Clin Oncol* 2022; **40**: 150-160 [PMID: [34648352](https://pubmed.ncbi.nlm.nih.gov/34648352/) DOI: [10.1200/JCO.21.00608](https://doi.org/10.1200/JCO.21.00608)]
- Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li SL, Deng HJ, He M, Mu LW, Zhao M. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). *J Clin Oncol* 2022; **40**: 468-480 [PMID: [34905388](https://pubmed.ncbi.nlm.nih.gov/34905388/) DOI: [10.1200/JCO.21.01963](https://doi.org/10.1200/JCO.21.01963)]
- Zhou SA, Zhou QM, Wu L, Chen ZH, Wu F, Chen ZR, Xu LQ, Gan BL, Jin HS, Shi N. Efficacy of hepatic arterial infusion chemotherapy and its combination strategies for advanced hepatocellular carcinoma: A network meta-analysis. *World J Gastrointest Oncol* 2024; **16**: 3672-3686 [PMID: [39171172](https://pubmed.ncbi.nlm.nih.gov/39171172/) DOI: [10.4251/wjgo.v16.i8.3672](https://doi.org/10.4251/wjgo.v16.i8.3672)]
- Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *N Engl J Med* 2020; **382**: 1894-1905 [PMID: [32402160](https://pubmed.ncbi.nlm.nih.gov/32402160/) DOI: [10.1056/NEJMoa1915745](https://doi.org/10.1056/NEJMoa1915745)]
- Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Van Dao T, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgué A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Marcovitz M, Makowsky M, He P, Kurland JF, Negro A, Sangro B. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. *NEJM Evid* 2022; **1**: EVIDoa2100070 [PMID: [38319892](https://pubmed.ncbi.nlm.nih.gov/38319892/) DOI: [10.1056/EVIDoa2100070](https://doi.org/10.1056/EVIDoa2100070)]
- Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J; ORIENT-32 study group. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. *Lancet Oncol* 2021; **22**: 977-990 [PMID: [34143971](https://pubmed.ncbi.nlm.nih.gov/34143971/) DOI: [10.1016/S1470-2045\(21\)00252-7](https://doi.org/10.1016/S1470-2045(21)00252-7)]
- Decaens T, Yau T, Kudo M, Sangro B, Qin S, Da Fonseca L, Karachiwala H, Park JW, Gane E, Pinter M, Tai DWM, Santoro A, Pizarro G, Chiu CF, Schenker M, He AR, Wang Q, Ogata T, Hreiki J, Galle PR. 965MO Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): Expanded analyses from CheckMate 9DW. *Ann Oncol* 2024; **35** Suppl 2: S657
- Lencioni R, Kudo M, Erinjeri J, Qin S, Ren Z, Chan S, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon J, Tak WY, Suttichaimongkol T, Bouattour M, Lin S, Żotkiewicz M, Udoye S, Cohen G, Sangro B. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. *J Clin Oncol* 2024; **42**: LBA432-LBA432 [DOI: [10.1200/jco.2024.42.3_suppl.lba432](https://doi.org/10.1200/jco.2024.42.3_suppl.lba432)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: office@baishideng.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

